Cellectar Biosciences Inc
NASDAQ:CLRB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cellectar Biosciences Inc
Other Items
Cellectar Biosciences Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$4.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Other Items
$404.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$507.8m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cellectar Biosciences Inc
Glance View
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 12 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through Phospholipid Drug Conjugate (PDC) platform, is focused on to develop PDCs that are designed to target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The Company’s product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The firm is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase II CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase II CLOVER-2 study.
